Skip to main content

NCT01962974 - A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Available


Primary Citation

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Golimumab
Product Name
SIMPONI®
Therapeutic Area
Muscle, Bone, and Cartilage Diseases
Enrollment
7
% Female
100.0%
% White
N/A
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
CNTO148ART3003
Data Partner
Johnson & Johnson
Condition Studied
Arthritis, Rheumatoid
Mean/Median Age (Years)
60.0

Supporting Documentation

Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.